Kaplan-Meier curves of FLT3-ITD, DNMT3A, and NPM1 mutant AML, by treatment assignment. Data for overall survival from the intention-to-treat analysis are shown for patients with (A) FLT3-ITD, (B) DNMT3A, and (C) NPM1 mutant AML according to assignment to SD daunorubicin (45 mg/m2 per day) or HD daunorubicin (90 mg/m2 per day).